TTFields is a frequency-tuned, anti-mitotic, physical treatment modality delivered to the brain through a patient-operated, portable medical device called Optune. Results of a pre-specific successful interim analysis of the international, phase 3 trial (ClinicalTrials.gov Identifier: NCT00916409) comparing TTFields and temozolomide with temozolomide alone after radiotherapy and adjuvant temozolomide led to the approval of TTFields for the treatment of adult patients with glioblastoma.

The 2-year, 3-year, and 4-year survival rates were also significantly better for patients in the TTFields arm (P < .05 for all time points).

Within 7 weeks after the end of radiation treatment and adjuvant temozolomide, newly diagnosed patients with non-progressive disease were randomly assigned 2:1 to temozolomide 5 days per week plus continuous administration of TTFields or temozolomide alone.

CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients.

Our mission is to provide practice-focused clinical and drug information that is reflective of current and emerging principles of care that will help to inform oncology decisions.